Answers are grounded in this paper and cite their sources.
Objective To evaluate the clinical efficacy, onset characteristics, and safety of intense pulsed light (IPL) combined with conventional therapy for the treatment of moderate-to-severe video display terminal (VDT)-associated dry eye. Methods A retrospective controlled study was conducted on 100 patients (200 eyes) diagnosed with moderate-to-severe VDT-associated dry eye from June 2022 to September 2026. All enrolled patients were divided into two groups: Group A (50 patients, 100 eyes) received combined treatment with meibomian gland expression and topical medications, while Group B (50 patients, 100 eyes) received additional IPL therapy on the basis of the conventional regimen. Outcome measures including the ocular surface disease index (OSDI), non-invasive tear meniscus height (NITMH), non-invasive break up time (NIBUT), schirmer I test (SIT), eyelid margin score (EMS), meibomian gland yielding secretion score (MGYSS), corneal fluorescein staining score (CFSS), and meibomian gland loss score (MGLS) were assessed at baseline, 1 week, 4 weeks, 7 weeks, and 10 weeks after treatment. Generalized estimating equations were applied to address the correlation of binocular data, and repeated-measures analysis of variance and non-parametric tests were used for statistical analysis. Results At 10 weeks post-treatment, all dry eye-related indicators were significantly improved in Group A except for MGLS, whereas all indicators were remarkably ameliorated in Group B. Group B exhibited significantly superior improvements in OSDI, NITMH, NIBUT, SIT, EMS, MGYSS, and CFSS compared with Group A, with no significant between-group difference observed in MGLS. Moreover, Group B achieved obvious therapeutic effects as early as 1 week after treatment, while stable clinical improvements were only observed at 4 weeks in Group A. No severe adverse events occurred in either group throughout the follow-up period. Conclusion IPL combined with conventional therapy provides faster and more robust therapeutic efficacy with favorable safety for moderate-to-severe VDT-associated dry eye. This combined regimen can be recommended as a first-line adjuvant therapeutic strategy for such patients.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: